What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence for clinical effectiveness is primarily based on single-arm studies (WU-KONG1B and WU-KONG6) without a comparator arm, reporting an overall response rate (ORR) of 46% and 61% respectively. The lack of head-to-head comparisons against standard-of-care (SOC) limits the ability to claim superiority, thus justifying a B++ rating for comparable efficacy.
Does the economic case hold at the expected price? — Cost effectiveness
No incremental cost, QALY, or ICER results were reported in the available evidence. The lack of any cost-effectiveness analysis or economic modeling renders this factor unassessable, resulting in a C rating.
Is there quality-of-life evidence payers weigh? — Quality of life
No validated HRQoL instruments or utility values were reported in the retrieved sources. The absence of any HRQoL data indicates a critical gap in understanding the treatment’s impact on patient well-being, leading to a C rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile indicates manageable adverse events, with grade ³3 treatment-related adverse events reported at moderate levels (e.g., diarrhea 18% at 300 mg). While there are serious adverse events like interstitial lung disease (5%), the overall safety profile is acceptable, justifying an A rating.
Was the drug compared against what payers expect? — Comparator Selection
The ongoing confirmatory phase 3 trial (WU-KONG28) compares sunvozertinib to platinum-doublet chemotherapy, which is a relevant SOC. However, the absence of direct comparative data in the current evidence limits the strength of this factor, leading to a B++ rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The WU-KONG1B trial is multinational, providing a broader representation of the patient population, while WU-KONG6 is limited to China. The subgroup analyses reported in WU-KONG1B enhance the understanding of treatment effects across different demographics, justifying an A+ rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing pathways with the requirement for an FDA-approved diagnostic test. The indication for use after platinum-based chemotherapy aligns with current treatment sequences, supporting an A rating.
Are the wider system costs understood? — Resource Use and Cost Implications
No data on direct medical costs, implementation costs, or cost offsets were available in the retrieved sources. This absence of information leads to a C rating due to unsustainable budget impact concerns.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily derived from phase II studies with single-arm designs, which limits robustness. While there is consistency in reported ORR, the reliance on surrogate endpoints and lack of confirmatory data leads to a B+ rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty exists due to the accelerated approval status and the requirement for ongoing confirmatory trials. The absence of economic and HRQoL data further complicates the assessment, justifying a B+ rating.
